Review



2- bromoacetophenone (brap  (Millipore)


Bioz Verified Symbol Millipore is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Millipore 2- bromoacetophenone (brap
    2 Bromoacetophenone (Brap, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brap/2+bromoacetophenone/pm37797501-39-5-22
    Average 90 stars, based on 1 article reviews
    2- bromoacetophenone (brap - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Hydroxide catalysts for lignin depolymerization
    Article Snippet: 2-bromoacetophenone, phenol, potassium carbonate, potassium iodide, sodium borohydride, magnesium sulphate, nickel nitrate, and hydrotalcite were all purchased from Sigma-Aldrich and used as received.

    Article Title: Carboxyl groups on carbon nanodots as co-reactant sites for anodic electrochemiluminescence of tris(2,2-bipyridine)ruthenium(II).
    Article Snippet: The three typical oxygen-containing functional groups on C-dots have been selectively deactivated to elucidate their impact on the co-reactant behavior of C-dots, and the carboxyl groups on C-dots are revealed for the first time as co-reactant sites for Ru(bpy)3-ECL.

    Article Title: Cytomegalovirus inhibitor compounds
    Article Snippet: 2-Bromoacetophenone (Aldrich) (1.35 g, 6.80 mmol, 2.00 eq) and potassium carbonate (940 mg, 6.80 mmol, 2.00 eq) are added.

    Article Title: Design and Development of Axially Chiral Bis(naphthofuran) Luminogens as Fluorescent Probes for Cell Imaging.
    Article Snippet: Designing chiral AIEgens without aggregation-induced emission (AIE)-active molecules externally tagged to the chiral scaffold remains a long-standing challenge for the scientific community.. The inherent aggregation-caused quenching phenomenon associated with the axially chiral (R)-[1,1’-binaphthalene]-2,2’-diol ((R)-BINOL) scaffold, together with its marginal Stokes shift, limits its application as a chiral AIE-active material.. Here, in our effort to design chiral luminogens, we have developed a design strategy in which 2-substituted furans, when appropriately fused with the BINOL scaffold, will generate solid-state emissive materials with high thermal and photostability as well as colour-tunable properties.

    Article Title: Hydroxide catalysts for lignin depolymerization
    Article Snippet: 2-bromoacetophenone, phenol, potassium carbonate, potassium iodide, sodium borohydride, magnesium sulphate, nickel nitrate, and hydrotalcite were all purchased from Sigma-Aldrich and used as received.

    Article Title: Beneficial stilbene-based derivatives: From the synthesis of new catalytic photosensitizer to 3D printouts and fiber-reinforced composites
    Article Snippet: For the experiments with the type II photoinitiating system EDB: ethyl 4- (dimethylamino)benzoate (from Sigma Aldrich) and 2-Bromoacetophenone (BROMIDE, from Sigma Aldrich) were applied as an electron donor and acceptor in this systems.

    Article Title: Chemoenzymatic Synthesis of Enantiopure Amino Alcohols from Simple Methyl Ketones
    Article Snippet: Chemicals: NaCN (� 97%) and NH4Cl (99.5%) were obtained from Fluka (Switzerland), 2-Hydroxy acetophenone (98%), 4-Flourobenzaldehyde (98%), 4-Bromobenzaldehyde (99%), 2-Chloroacetophenone (97%), 3-Chloroacetophenone (98%), 2-Bromoacetophenone (99%), 3-Bromoacetophenone (99%), Cyclopentyl methyl ether (CPME) (99.9%) and Sodium formate (>99%) were purchased from Sigma-Aldrich (Taufkirchen, Germany), 3-Chlorobenzaldehyde (> 98%), 2-Bromobenzaldehyde (>98%), 2-Fluoroacetophenone (> 97%) and 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl isothiocyanate were obtained from TCI (Eschborn, Germany), 2-Fluorobenzaldehyde (99%), 4’-Fluoro-2-hydroxyacetophenone (95%) and 4’- Bromo-2-hydroxyacetophenone were purchased from Apollo Scientific (Bredbury, UK) and PLP (98%) was obtained from fluorochem (Hadfield, United Kingdom), 3-Fluoroacetophenone (99%) and (R)( )-2-Phenylglycinol (98%) were purchased from Acros Organics (Geel, Belgium), LiAlH4 (>95%), 3-Bromobenzaldehyde (97%), 4- Chlorobenzaldehyde (98%) and 2-Flourobenzaldehyde (97%) were obtained from Thermo Scientific (Germany), HEPES (�99%), NaOH (98.7%) and HCl solution (32%) was purchased from Fisher Scientific (Schwerte, Germany), NaH2PO4 (�98%) was obtained from Merck (Darmstadt, Germany), 4'-Chloro-2-hydroxyacetophenone (95%) was purchased from BIONET Key Organics (Camelford, UK) and 2-amino-1-(3-fluorophenyl)ethan-1-ol (>90%) was obtained Life Chemicals (Woodbridge, USA). (2R)-2-Amino-2(4chlorophenyl)ethan-1-ol (>95% ee) and (S)-2-Amino-2-(3-chlorophenyl)-ethanol (>95% ee) were purchased from activate-scientific (Prien, Germany).

    Article Title: Design, synthesis, and antiproliferative activities of novel thiazolyl-pyrazole hybrid derivatives
    Article Snippet: In this study, a series of derivatives of thiazolyl-pyrazole hybrid structures were designed to search for new heterocyclic compound-based antitumor agents.. The designed target structures were synthesized with easy, practical, and efficient procedures.. The antiproliferative effect of the synthesized compounds against cancer cell lines A549, MCF-7, and HepG2 was evaluated regarding inhibition concentration and selectivity index against healthy cell line CCD-34Lu.



    Similar Products

    93
    Thermo Fisher gene exp brap mm00518493 m1
    Gene Exp Brap Mm00518493 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brap/Gene+Exp%2E+Brap%2C+Mm00518493_m1/pmc10810990-101-15-2
    Average 93 stars, based on 1 article reviews
    gene exp brap mm00518493 m1 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    86
    Danaher Inc antibody against human brap
    TSLP expression was increased by down-regulation of <t>BRAP</t> or its mouse homolog. (A) Double immunofluorescence staining by IL-23 and CD11c in skin tissue sections from IMQ treated mice (magnification: 200×); scale bar = 100 μm. Immunostaining with IL-23 antibody was shown as red fluorescence. Immunostaining using antibodies against CD11c was shown as green fluorescence. Nuclei of the cells were localized by DAPI (blue). The orange signals in the merged picture, some of which were shown by red arrows, indicate the co-distribution of IL-23 and CD11c in the cytoplasm of cells. (B) Immunohistochemistry analysis of skin tissue sections using TSLP antibody. Day 0 indicates that the samples were made before the first IMQ application. (C) Daily serum levels of TSLP during the 7-day IMQ treatment as determined by ELISA. (D) Western blot analysis of BRAP expression in HaCaT cells transfected with siRNA to silence C6orf89 expression. (E) ELISA analysis of TSLP content in the culture media of HaCaT cells with C6orf89 expression silenced by siRNA transfection.
    Antibody Against Human Brap, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brap/pmc10758153-59-7-14
    Average 86 stars, based on 1 article reviews
    antibody against human brap - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    86
    Danaher Inc brap
    The expression of <t>BRAP</t> and its mouse homolog in skin tissues and the skin injury induced by IMQ in both BC004004 -/- mice and their wild type control mice. (A) The expression of BRAP in both normal human skin and the skin of patient with psoriasis by immunohistochemistry analysis of tissue samples with anti-BRAP antibody. BRAP is expressed in the epidermis of both normal skin tissue and skin tissue with psoriasis (magnification: 100×(scale bar = 200 μm) and 400×(scale bar = 50 μm)). (B) BRAP homologous protein was present in skin tissues as revealed by Western blotting in wild-type control mice BC004004 +/+ with imiquimod (IMQ) treatment for 7 day. The total protein extract from one wild type mice skin representing each day of IMQ treatment was loaded in one well. The expression of β-actin from the same sample was used as a loading control. (C) Representative photographs of psoriasis-like lesions on back skin of BC004004 +/+ mice and BC004004 -/- mice after 7 days of IMQ treatment. Vaseline treatment was applied on control groups as a vehicle control. (D) Daily body weights throughout the 7-day IMQ treatment were shown in the upper left panel. The characteristics of skin lesion were depicted as redness, scaling scores and thickness of back skin and scored according to a murine Psoriasis Area and Severity Index (PASI) score table. Data are presented as mean ± SD; n = 9 in each group. * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001.
    Brap, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brap/pmc10758153-48-9-10
    Average 86 stars, based on 1 article reviews
    brap - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    90
    Millipore 2- bromoacetophenone (brap
    The expression of <t>BRAP</t> and its mouse homolog in skin tissues and the skin injury induced by IMQ in both BC004004 -/- mice and their wild type control mice. (A) The expression of BRAP in both normal human skin and the skin of patient with psoriasis by immunohistochemistry analysis of tissue samples with anti-BRAP antibody. BRAP is expressed in the epidermis of both normal skin tissue and skin tissue with psoriasis (magnification: 100×(scale bar = 200 μm) and 400×(scale bar = 50 μm)). (B) BRAP homologous protein was present in skin tissues as revealed by Western blotting in wild-type control mice BC004004 +/+ with imiquimod (IMQ) treatment for 7 day. The total protein extract from one wild type mice skin representing each day of IMQ treatment was loaded in one well. The expression of β-actin from the same sample was used as a loading control. (C) Representative photographs of psoriasis-like lesions on back skin of BC004004 +/+ mice and BC004004 -/- mice after 7 days of IMQ treatment. Vaseline treatment was applied on control groups as a vehicle control. (D) Daily body weights throughout the 7-day IMQ treatment were shown in the upper left panel. The characteristics of skin lesion were depicted as redness, scaling scores and thickness of back skin and scored according to a murine Psoriasis Area and Severity Index (PASI) score table. Data are presented as mean ± SD; n = 9 in each group. * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001.
    2 Bromoacetophenone (Brap, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brap/2+bromoacetophenone/pm37797501-39-5-22
    Average 90 stars, based on 1 article reviews
    2- bromoacetophenone (brap - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    99
    New England Biolabs recombinant brap ctd
    The expression of <t>BRAP</t> and its mouse homolog in skin tissues and the skin injury induced by IMQ in both BC004004 -/- mice and their wild type control mice. (A) The expression of BRAP in both normal human skin and the skin of patient with psoriasis by immunohistochemistry analysis of tissue samples with anti-BRAP antibody. BRAP is expressed in the epidermis of both normal skin tissue and skin tissue with psoriasis (magnification: 100×(scale bar = 200 μm) and 400×(scale bar = 50 μm)). (B) BRAP homologous protein was present in skin tissues as revealed by Western blotting in wild-type control mice BC004004 +/+ with imiquimod (IMQ) treatment for 7 day. The total protein extract from one wild type mice skin representing each day of IMQ treatment was loaded in one well. The expression of β-actin from the same sample was used as a loading control. (C) Representative photographs of psoriasis-like lesions on back skin of BC004004 +/+ mice and BC004004 -/- mice after 7 days of IMQ treatment. Vaseline treatment was applied on control groups as a vehicle control. (D) Daily body weights throughout the 7-day IMQ treatment were shown in the upper left panel. The characteristics of skin lesion were depicted as redness, scaling scores and thickness of back skin and scored according to a murine Psoriasis Area and Severity Index (PASI) score table. Data are presented as mean ± SD; n = 9 in each group. * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001.
    Recombinant Brap Ctd, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brap/Amylose+Resin/pm37715941-69-55-66
    Average 99 stars, based on 1 article reviews
    recombinant brap ctd - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    90
    Cusabio brap
    Figure 2. The analysis of behavioral tests after exposure to chronic unpredictable mild stress (CUMS). (A) Body weight changes throughout the CUMS procedure. (B) Immobility time of bc004004þ/þ and bc004004 / mice in the forced swimming test with treatment of CUMS. (C) Analysis of sucrose preference tests during the CUMS procedure. (D) Immobility time of bc004004þ/þ and bc004004 / mice in the tail suspension test after 21-day CUMS exposure. (E) Total distance traveled in the different regions in the open field test after 21-day CUMS exposure. Two-way ANOVA was performed followed by Tukey’s multiple comparisons. (F) The expres sion of <t>BRAP</t> homologous protein in mice detected by western blot <t>with</t> <t>anti-BRAP</t> antibody. The protein extracts of hippocampus tissues of the mice was used in western blot after 21-day of CUMS treatment. The expression of b-actin from the same sample was used as loading controls. Data are presented as mean ± SD. p <.05, p <.01, p <.001,p <.0001, n ¼ 8.
    Brap, supplied by Cusabio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brap/Rabbit+anti-Human+GRIN2A+Polyclonal+Antibody/pm36520154-112-30-36
    Average 90 stars, based on 1 article reviews
    brap - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    86
    Sangon Biotech brap
    Figure 2. The analysis of behavioral tests after exposure to chronic unpredictable mild stress (CUMS). (A) Body weight changes throughout the CUMS procedure. (B) Immobility time of bc004004þ/þ and bc004004 / mice in the forced swimming test with treatment of CUMS. (C) Analysis of sucrose preference tests during the CUMS procedure. (D) Immobility time of bc004004þ/þ and bc004004 / mice in the tail suspension test after 21-day CUMS exposure. (E) Total distance traveled in the different regions in the open field test after 21-day CUMS exposure. Two-way ANOVA was performed followed by Tukey’s multiple comparisons. (F) The expres sion of <t>BRAP</t> homologous protein in mice detected by western blot <t>with</t> <t>anti-BRAP</t> antibody. The protein extracts of hippocampus tissues of the mice was used in western blot after 21-day of CUMS treatment. The expression of b-actin from the same sample was used as loading controls. Data are presented as mean ± SD. p <.05, p <.01, p <.001,p <.0001, n ¼ 8.
    Brap, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brap/anti+anti+anti+brap/pm36520154-112-30-41
    Average 86 stars, based on 1 article reviews
    brap - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    Image Search Results


    TSLP expression was increased by down-regulation of BRAP or its mouse homolog. (A) Double immunofluorescence staining by IL-23 and CD11c in skin tissue sections from IMQ treated mice (magnification: 200×); scale bar = 100 μm. Immunostaining with IL-23 antibody was shown as red fluorescence. Immunostaining using antibodies against CD11c was shown as green fluorescence. Nuclei of the cells were localized by DAPI (blue). The orange signals in the merged picture, some of which were shown by red arrows, indicate the co-distribution of IL-23 and CD11c in the cytoplasm of cells. (B) Immunohistochemistry analysis of skin tissue sections using TSLP antibody. Day 0 indicates that the samples were made before the first IMQ application. (C) Daily serum levels of TSLP during the 7-day IMQ treatment as determined by ELISA. (D) Western blot analysis of BRAP expression in HaCaT cells transfected with siRNA to silence C6orf89 expression. (E) ELISA analysis of TSLP content in the culture media of HaCaT cells with C6orf89 expression silenced by siRNA transfection.

    Journal: International Journal of Medical Sciences

    Article Title: Bombesin receptor-activated protein homolog deficiency altered the pattern of pathological changes of psoriasis - like skin lesion in mice

    doi: 10.7150/ijms.89492

    Figure Lengend Snippet: TSLP expression was increased by down-regulation of BRAP or its mouse homolog. (A) Double immunofluorescence staining by IL-23 and CD11c in skin tissue sections from IMQ treated mice (magnification: 200×); scale bar = 100 μm. Immunostaining with IL-23 antibody was shown as red fluorescence. Immunostaining using antibodies against CD11c was shown as green fluorescence. Nuclei of the cells were localized by DAPI (blue). The orange signals in the merged picture, some of which were shown by red arrows, indicate the co-distribution of IL-23 and CD11c in the cytoplasm of cells. (B) Immunohistochemistry analysis of skin tissue sections using TSLP antibody. Day 0 indicates that the samples were made before the first IMQ application. (C) Daily serum levels of TSLP during the 7-day IMQ treatment as determined by ELISA. (D) Western blot analysis of BRAP expression in HaCaT cells transfected with siRNA to silence C6orf89 expression. (E) ELISA analysis of TSLP content in the culture media of HaCaT cells with C6orf89 expression silenced by siRNA transfection.

    Article Snippet: As illustrated by IHC analysis using an antibody against human BRAP (EPR13621, cat: ab181073, Abcam), BRAP was expressed in various cells from both epidermis and dermis.

    Techniques: Expressing, Double Immunofluorescence Staining, Immunostaining, Fluorescence, Immunohistochemistry, Enzyme-linked Immunosorbent Assay, Western Blot, Transfection

    The expression of BRAP and its mouse homolog in skin tissues and the skin injury induced by IMQ in both BC004004 -/- mice and their wild type control mice. (A) The expression of BRAP in both normal human skin and the skin of patient with psoriasis by immunohistochemistry analysis of tissue samples with anti-BRAP antibody. BRAP is expressed in the epidermis of both normal skin tissue and skin tissue with psoriasis (magnification: 100×(scale bar = 200 μm) and 400×(scale bar = 50 μm)). (B) BRAP homologous protein was present in skin tissues as revealed by Western blotting in wild-type control mice BC004004 +/+ with imiquimod (IMQ) treatment for 7 day. The total protein extract from one wild type mice skin representing each day of IMQ treatment was loaded in one well. The expression of β-actin from the same sample was used as a loading control. (C) Representative photographs of psoriasis-like lesions on back skin of BC004004 +/+ mice and BC004004 -/- mice after 7 days of IMQ treatment. Vaseline treatment was applied on control groups as a vehicle control. (D) Daily body weights throughout the 7-day IMQ treatment were shown in the upper left panel. The characteristics of skin lesion were depicted as redness, scaling scores and thickness of back skin and scored according to a murine Psoriasis Area and Severity Index (PASI) score table. Data are presented as mean ± SD; n = 9 in each group. * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001.

    Journal: International Journal of Medical Sciences

    Article Title: Bombesin receptor-activated protein homolog deficiency altered the pattern of pathological changes of psoriasis - like skin lesion in mice

    doi: 10.7150/ijms.89492

    Figure Lengend Snippet: The expression of BRAP and its mouse homolog in skin tissues and the skin injury induced by IMQ in both BC004004 -/- mice and their wild type control mice. (A) The expression of BRAP in both normal human skin and the skin of patient with psoriasis by immunohistochemistry analysis of tissue samples with anti-BRAP antibody. BRAP is expressed in the epidermis of both normal skin tissue and skin tissue with psoriasis (magnification: 100×(scale bar = 200 μm) and 400×(scale bar = 50 μm)). (B) BRAP homologous protein was present in skin tissues as revealed by Western blotting in wild-type control mice BC004004 +/+ with imiquimod (IMQ) treatment for 7 day. The total protein extract from one wild type mice skin representing each day of IMQ treatment was loaded in one well. The expression of β-actin from the same sample was used as a loading control. (C) Representative photographs of psoriasis-like lesions on back skin of BC004004 +/+ mice and BC004004 -/- mice after 7 days of IMQ treatment. Vaseline treatment was applied on control groups as a vehicle control. (D) Daily body weights throughout the 7-day IMQ treatment were shown in the upper left panel. The characteristics of skin lesion were depicted as redness, scaling scores and thickness of back skin and scored according to a murine Psoriasis Area and Severity Index (PASI) score table. Data are presented as mean ± SD; n = 9 in each group. * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001.

    Article Snippet: The following antibodies and their corresponding dilutions were used: BRAP (Abcam, cat: ab181073; 1:2,000), IL-23 (Santa Cruz, cat: sc-271279,1:1,000;), IL-1β (Santa Cruz, cat: 12742,1:1,000), IL-10 (Santa Cruz, cat: 8438, 1:1,000), IL-17 (Affinity, cat: DF6127, 1:2,000), IL-17 (Santa Cruz, cat: sc-374218, 1:1,000), TNF-α (Santa Cruz, cat: sc-52746, 1:1,000), CK5 (Affinity, cat: AF5479, 1:2,000), β-Actin (Santa Cruz, cat: sc-47778, 1:5,000), CK14 (Santa Cruz, cat: sc-53253, 1:1,000), TGF-β1 (Abcam, cat: ab64715, 1:2,000), HRP-conjugated goat anti-Mouse IgG (H+L) (Proteintech, cat: SA00001-1, 1:5,000), HRP-conjugated goat anti-rabbit IgG(H+L) (SouthernBiotech, cat: 4050-05; 1: 5,000).

    Techniques: Expressing, Immunohistochemistry, Western Blot

    TSLP expression was increased by down-regulation of BRAP or its mouse homolog. (A) Double immunofluorescence staining by IL-23 and CD11c in skin tissue sections from IMQ treated mice (magnification: 200×); scale bar = 100 μm. Immunostaining with IL-23 antibody was shown as red fluorescence. Immunostaining using antibodies against CD11c was shown as green fluorescence. Nuclei of the cells were localized by DAPI (blue). The orange signals in the merged picture, some of which were shown by red arrows, indicate the co-distribution of IL-23 and CD11c in the cytoplasm of cells. (B) Immunohistochemistry analysis of skin tissue sections using TSLP antibody. Day 0 indicates that the samples were made before the first IMQ application. (C) Daily serum levels of TSLP during the 7-day IMQ treatment as determined by ELISA. (D) Western blot analysis of BRAP expression in HaCaT cells transfected with siRNA to silence C6orf89 expression. (E) ELISA analysis of TSLP content in the culture media of HaCaT cells with C6orf89 expression silenced by siRNA transfection.

    Journal: International Journal of Medical Sciences

    Article Title: Bombesin receptor-activated protein homolog deficiency altered the pattern of pathological changes of psoriasis - like skin lesion in mice

    doi: 10.7150/ijms.89492

    Figure Lengend Snippet: TSLP expression was increased by down-regulation of BRAP or its mouse homolog. (A) Double immunofluorescence staining by IL-23 and CD11c in skin tissue sections from IMQ treated mice (magnification: 200×); scale bar = 100 μm. Immunostaining with IL-23 antibody was shown as red fluorescence. Immunostaining using antibodies against CD11c was shown as green fluorescence. Nuclei of the cells were localized by DAPI (blue). The orange signals in the merged picture, some of which were shown by red arrows, indicate the co-distribution of IL-23 and CD11c in the cytoplasm of cells. (B) Immunohistochemistry analysis of skin tissue sections using TSLP antibody. Day 0 indicates that the samples were made before the first IMQ application. (C) Daily serum levels of TSLP during the 7-day IMQ treatment as determined by ELISA. (D) Western blot analysis of BRAP expression in HaCaT cells transfected with siRNA to silence C6orf89 expression. (E) ELISA analysis of TSLP content in the culture media of HaCaT cells with C6orf89 expression silenced by siRNA transfection.

    Article Snippet: The following antibodies and their corresponding dilutions were used: BRAP (Abcam, cat: ab181073; 1:2,000), IL-23 (Santa Cruz, cat: sc-271279,1:1,000;), IL-1β (Santa Cruz, cat: 12742,1:1,000), IL-10 (Santa Cruz, cat: 8438, 1:1,000), IL-17 (Affinity, cat: DF6127, 1:2,000), IL-17 (Santa Cruz, cat: sc-374218, 1:1,000), TNF-α (Santa Cruz, cat: sc-52746, 1:1,000), CK5 (Affinity, cat: AF5479, 1:2,000), β-Actin (Santa Cruz, cat: sc-47778, 1:5,000), CK14 (Santa Cruz, cat: sc-53253, 1:1,000), TGF-β1 (Abcam, cat: ab64715, 1:2,000), HRP-conjugated goat anti-Mouse IgG (H+L) (Proteintech, cat: SA00001-1, 1:5,000), HRP-conjugated goat anti-rabbit IgG(H+L) (SouthernBiotech, cat: 4050-05; 1: 5,000).

    Techniques: Expressing, Double Immunofluorescence Staining, Immunostaining, Fluorescence, Immunohistochemistry, Enzyme-linked Immunosorbent Assay, Western Blot, Transfection

    Figure 2. The analysis of behavioral tests after exposure to chronic unpredictable mild stress (CUMS). (A) Body weight changes throughout the CUMS procedure. (B) Immobility time of bc004004þ/þ and bc004004 / mice in the forced swimming test with treatment of CUMS. (C) Analysis of sucrose preference tests during the CUMS procedure. (D) Immobility time of bc004004þ/þ and bc004004 / mice in the tail suspension test after 21-day CUMS exposure. (E) Total distance traveled in the different regions in the open field test after 21-day CUMS exposure. Two-way ANOVA was performed followed by Tukey’s multiple comparisons. (F) The expres sion of BRAP homologous protein in mice detected by western blot with anti-BRAP antibody. The protein extracts of hippocampus tissues of the mice was used in western blot after 21-day of CUMS treatment. The expression of b-actin from the same sample was used as loading controls. Data are presented as mean ± SD. p <.05, p <.01, p <.001,p <.0001, n ¼ 8.

    Journal: Stress (Amsterdam, Netherlands)

    Article Title: Lack of bombesin receptor-activated protein homologous protein impairs hippocampal synaptic plasticity and promotes chronic unpredictable mild stress induced behavioral changes in mice.

    doi: 10.1080/10253890.2022.2155513

    Figure Lengend Snippet: Figure 2. The analysis of behavioral tests after exposure to chronic unpredictable mild stress (CUMS). (A) Body weight changes throughout the CUMS procedure. (B) Immobility time of bc004004þ/þ and bc004004 / mice in the forced swimming test with treatment of CUMS. (C) Analysis of sucrose preference tests during the CUMS procedure. (D) Immobility time of bc004004þ/þ and bc004004 / mice in the tail suspension test after 21-day CUMS exposure. (E) Total distance traveled in the different regions in the open field test after 21-day CUMS exposure. Two-way ANOVA was performed followed by Tukey’s multiple comparisons. (F) The expres sion of BRAP homologous protein in mice detected by western blot with anti-BRAP antibody. The protein extracts of hippocampus tissues of the mice was used in western blot after 21-day of CUMS treatment. The expression of b-actin from the same sample was used as loading controls. Data are presented as mean ± SD. p <.05, p <.01, p <.001,p <.0001, n ¼ 8.

    Article Snippet: The transferred PVDF membranes were incubated with the following primary antibodies with dilutions indicated respectively: b-actin (Sigma, cat: A5441, 1:10,000), BDNF (Abcam, cat: ab108319, 1:1000), Trk-B (Boster, cat: BA0623, 1:1000), BRAP (Abcam, cat: ab181073, 1:1000), GluN2A (CUSABIO, cat: CSB-PA14129A0Rb, 1:500), PSD95 (Sangon Biotech, cat: D261092, 1:500), synaptophysin (ABclonal, cat: A6344, 1:1000).

    Techniques: Suspension, Western Blot, Expressing

    Figure 2. The analysis of behavioral tests after exposure to chronic unpredictable mild stress (CUMS). (A) Body weight changes throughout the CUMS procedure. (B) Immobility time of bc004004þ/þ and bc004004 / mice in the forced swimming test with treatment of CUMS. (C) Analysis of sucrose preference tests during the CUMS procedure. (D) Immobility time of bc004004þ/þ and bc004004 / mice in the tail suspension test after 21-day CUMS exposure. (E) Total distance traveled in the different regions in the open field test after 21-day CUMS exposure. Two-way ANOVA was performed followed by Tukey’s multiple comparisons. (F) The expres sion of BRAP homologous protein in mice detected by western blot with anti-BRAP antibody. The protein extracts of hippocampus tissues of the mice was used in western blot after 21-day of CUMS treatment. The expression of b-actin from the same sample was used as loading controls. Data are presented as mean ± SD. p <.05, p <.01, p <.001,p <.0001, n ¼ 8.

    Journal: Stress (Amsterdam, Netherlands)

    Article Title: Lack of bombesin receptor-activated protein homologous protein impairs hippocampal synaptic plasticity and promotes chronic unpredictable mild stress induced behavioral changes in mice.

    doi: 10.1080/10253890.2022.2155513

    Figure Lengend Snippet: Figure 2. The analysis of behavioral tests after exposure to chronic unpredictable mild stress (CUMS). (A) Body weight changes throughout the CUMS procedure. (B) Immobility time of bc004004þ/þ and bc004004 / mice in the forced swimming test with treatment of CUMS. (C) Analysis of sucrose preference tests during the CUMS procedure. (D) Immobility time of bc004004þ/þ and bc004004 / mice in the tail suspension test after 21-day CUMS exposure. (E) Total distance traveled in the different regions in the open field test after 21-day CUMS exposure. Two-way ANOVA was performed followed by Tukey’s multiple comparisons. (F) The expres sion of BRAP homologous protein in mice detected by western blot with anti-BRAP antibody. The protein extracts of hippocampus tissues of the mice was used in western blot after 21-day of CUMS treatment. The expression of b-actin from the same sample was used as loading controls. Data are presented as mean ± SD. p <.05, p <.01, p <.001,p <.0001, n ¼ 8.

    Article Snippet: The transferred PVDF membranes were incubated with the following primary antibodies with dilutions indicated respectively: b-actin (Sigma, cat: A5441, 1:10,000), BDNF (Abcam, cat: ab108319, 1:1000), Trk-B (Boster, cat: BA0623, 1:1000), BRAP (Abcam, cat: ab181073, 1:1000), GluN2A (CUSABIO, cat: CSB-PA14129A0Rb, 1:500), PSD95 (Sangon Biotech, cat: D261092, 1:500), synaptophysin (ABclonal, cat: A6344, 1:1000).

    Techniques: Suspension, Western Blot, Expressing